Cellebrite DI Ltd. (NASDAQ:CLBT) Given Consensus Rating of “Moderate Buy” by Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $21.75.

A number of research analysts have commented on the stock. Lake Street Capital decreased their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. Wall Street Zen upgraded shares of Cellebrite DI from a “hold” rating to a “buy” rating in a report on Friday, September 26th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, August 14th. JPMorgan Chase & Co. upped their price target on Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Cellebrite DI in a research report on Wednesday.

Cellebrite DI Stock Performance

CLBT stock opened at $18.99 on Thursday. Cellebrite DI has a one year low of $13.10 and a one year high of $26.30. The firm has a market cap of $4.55 billion, a PE ratio of -24.99, a PEG ratio of 3.36 and a beta of 1.29. The firm’s 50 day moving average price is $16.50 and its 200-day moving average price is $16.98.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same period in the prior year, the business posted $0.10 earnings per share. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. acquired a new stake in Cellebrite DI in the 1st quarter valued at about $60,939,000. Invesco Ltd. raised its holdings in Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company’s stock valued at $64,043,000 after acquiring an additional 1,811,757 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in Cellebrite DI by 749.9% in the first quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company’s stock worth $29,508,000 after acquiring an additional 1,340,000 shares during the last quarter. Voss Capital LP lifted its stake in Cellebrite DI by 34.0% in the second quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock worth $82,400,000 after acquiring an additional 1,306,398 shares during the last quarter. Finally, Phoenix Financial Ltd. lifted its stake in Cellebrite DI by 153.5% in the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company’s stock worth $32,232,000 after acquiring an additional 1,219,958 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.